High Systemic Inflammation Response Index (SIRI) Indicates Poor Outcome in Gallbladder Cancer Patients with Surgical Resection: A Single Institution Experience in China.
Aged
Blood Loss, Surgical
/ statistics & numerical data
China
/ epidemiology
Cholecystectomy
Female
Follow-Up Studies
Gallbladder
/ pathology
Gallbladder Neoplasms
/ complications
Humans
Kaplan-Meier Estimate
Length of Stay
Male
Middle Aged
Neoplasm Staging
Nomograms
Preoperative Period
ROC Curve
Reference Values
Retrospective Studies
Risk Assessment
/ methods
Severity of Illness Index
Systemic Inflammatory Response Syndrome
/ diagnosis
Gallbladder neoplasms
Nomogram
Overall survival
Prognosis
Systemic inflammation response index (SIRI)
Journal
Cancer research and treatment
ISSN: 2005-9256
Titre abrégé: Cancer Res Treat
Pays: Korea (South)
ID NLM: 101155137
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
13
04
2020
accepted:
20
07
2020
pubmed:
29
7
2020
medline:
22
6
2021
entrez:
29
7
2020
Statut:
ppublish
Résumé
The systemic inflammation response index (SIRI) has been reported to have prognostic ability in various solid tumors but has not been studied in gallbladder cancer (GBC). We aimed to determine its prognostic value in GBC. From 2003 to 2017, patients with confirmed GBC were recruited. To determine the SIRI's optimal cutoff value, a time-dependent receiver operating characteristic curve was applied. Univariate and multivariate Cox analyses were performed for the recognition of significant factors. Then the cohort was randomly divided into the training and the validation set. A nomogram was constructed using the SIRI and other selected indicators in the training set, and compared with the TNM staging system. C-index, calibration plots, and decision curve analysis were performed to assess the nomogram's clinical utility. One hundred twenty-four patients were included. The SIRI's optimal cutoff value divided patients into high (≥ 0.89) and low SIRI (< 0.89) groups. Kaplan-Meier curves according to SIRI levels were significantly different (p < 0.001). The high SIRI group tended to stay longer in hospital and lost more blood during surgery. SIRI, body mass index, weight loss, carbohydrate antigen 19-9, radical surgery, and TNM stage were combined to generate a nomogram (C-index, 0.821 in the training cohort, 0.828 in the validation cohort) that was significantly superior to the TNM staging system both in the training (C-index, 0.655) and validation cohort (C-index, 0.649). The SIRI is an independent predictor of prognosis in GBC. A nomogram based on the SIRI may help physicians to precisely stratify patients and implement individualized treatment.
Identifiants
pubmed: 32718144
pii: crt.2020.303
doi: 10.4143/crt.2020.303
pmc: PMC7577819
doi:
Types de publication
Journal Article
Observational Study
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1199-1210Subventions
Organisme : CAMS Innovation Fund for Medical Sciences
ID : 2016-I2M-1-001
Organisme : Tsinghua University-Peking Union Medical College Hospital Cooperation Project
ID : PTQH201904552
Références
World J Gastroenterol. 2018 Dec 7;24(45):5167-5178
pubmed: 30568393
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Cancer Res Clin Oncol. 2017 Dec;143(12):2455-2468
pubmed: 28828692
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Oncotarget. 2017 Jan 10;8(2):2329-2341
pubmed: 27911876
Pancreatology. 2016 Nov - Dec;16(6):1080-1084
pubmed: 27665172
AMA Arch Surg. 1958 Nov;77(5):742-50
pubmed: 13582435
Int Immunopharmacol. 2018 Dec;65:503-510
pubmed: 30408627
Science. 2014 May 23;344(6186):921-5
pubmed: 24812208
Hepatobiliary Surg Nutr. 2019 Oct;8(5):480-489
pubmed: 31673537
Cancer Res Treat. 2018 Oct;50(4):1444-1451
pubmed: 29370591
Cancer. 2019 Feb 15;125(4):575-585
pubmed: 30427539
BMC Cancer. 2017 Jun 5;17(1):404
pubmed: 28583114
Lung Cancer. 2017 Sep;111:176-181
pubmed: 28838390
Lancet Oncol. 2019 May;20(5):663-673
pubmed: 30922733
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
Gastroenterology. 2013 May;144(5):1031-1041.e10
pubmed: 23376424
HPB (Oxford). 2016 Nov;18(11):872-878
pubmed: 27527802
Ann Surg Oncol. 2016 Dec;23(13):4401-4409
pubmed: 27495279
J Investig Med. 2019 Mar;67(3):691-698
pubmed: 30127099
Cancer Res Treat. 2020 Apr;52(2):455-468
pubmed: 31623417
Cancer. 2016 Jul 15;122(14):2158-67
pubmed: 27152949
PLoS One. 2015 Aug 27;10(8):e0136252
pubmed: 26313661
Nature. 2001 May 17;411(6835):380-4
pubmed: 11357146
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
J Am Coll Dent. 2014 Summer;81(3):14-8
pubmed: 25951678
Hepatobiliary Surg Nutr. 2019 Oct;8(5):537-538
pubmed: 31673550
Hepatobiliary Surg Nutr. 2019 Dec;8(6):604-614
pubmed: 31929987
Gut. 2019 Jun;68(6):1024-1033
pubmed: 29954840
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468